Single dose epinephrine injections from Sandoz to retail at lower cost than generic EpiPens

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/MarianVejcik)
(Image: Getty/MarianVejcik)

Related tags: Sandoz, EpiPen, Drug shortages, Mylan, Teva, Novartis

Sandoz launches its epinephrine injection Sympjepi for retail across US pharmacies to mitigate the ‘chronic shortages’ of the drug.

Sympjepi (epinephrine) is launched​ in .3mg and .15mg pre-filled single dose injections at local pharmacies across the US, after being initially introduced to wholesales earlier this year at a price of $250​ (€218) per two-pack.

Mylan’s epinephrine autoinjector, EpiPen, retails at $600 for a pack of two, and its generic and Teva​’s have a price tag of $300 for a two-pack.

The drug was originally developed by Adamis but US rights were licensed to Sandoz, a division of Novartis, after Sympjepi received approval by the US Food and Drug Administration in June 2017.

With this launch, wholesaler customers of Sandoz can now stock the product to supply hospitals and clinics with both the adult and pediatric doses of Sympjepi in the US.

Dennis Carlo, president and CEO of Adamis, said that the launch of Sympjepi is expected to play a role in ending the chronic shortages​ of epinephrine injection products in the US. In 2018, EpiPen shortages occurred after a major epinephrine producer, Pfizer, experienced manufacturing difficulties.

Sandoz aims to use the launch as an initiative to modify existing state legislation to increase the availability of epinephrine in schools and to educate hospital providers and physicians on how to write scripts for epinephrine injection.

A spokesperson for Sandoz told us that this educational aspect of the launch to enable doctors to understand the option to prescribe a pre-filled single dose epinephrine injection instead of an auto-injector.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us


View more